Empleo de 225Ac y 213Bi como radioisótopos en la terapia alfa dirigida para tratamiento de cáncer

• Autores: Mayorga-Martino, Vanessa, Vélez Puyen, Tatiana E.
• Formato: artículo
• Fecha de Publicación: 2022
• Institución: Pontificia Universidad Católica del Perú
• Repositorio: PUCP-Institucional
• Lenguaje: español
• OAI Identifier: oai:repositorio.pucp.edu.pe:20.500.14657/193519
• Enlace del recurso: https://revistas.pucp.edu.pe/index.php/quimica/article/view/26266/24671; https://repositorio.pucp.edu.pe/index/handle/123456789/193519
• Nivel de acceso: acceso abierto
• Materia: Targeted α-therapy (TAT); Actinium-225; bismuth-213; Terapia alfa dirigida (TAT); Actinio-225; Bismuto-213; https://purl.org/pe-repo/ocde/ford#1.04.00

This manuscript introduces the concept of radioimmunotherapy in cancer, as well as the main advantages of targeted α-therapy (TAT) over other methods. The discussions focus mainly on the therapeutic use of 225Ac and 213Bi radioisotopes in the recent technique and their main advantages over conventional methods. The properties of these radionuclides and their means of extraction and production are also discussed. Then, their fundamental properties are discussed along with the coordination chemistry of both isotopes. In addition, an overview of considerations for radiopharmaceutical design, and available bifunctional chelating agents for actinium and bismuth, is provided. Finally, some preclinical and clinical studies involving both isotopes are described, as well as the future perspectives of this promising treatment for cancer.